epacadostat
epacadostat: 26 clinical trials tracked.
epacadostat evidence translation
What we can confirm
26 tracked trials
What it means
What to watch
Prepared research question
What is verified about epacadostat, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trials (26)showing 10 most recent
An Open-Label, Randomized, Phase 2, Umbrella Study to Investigate the Biological Rational of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
Primary endpoint: Change From Baseline in CD8+ Lymphocytes Within the Resected Tumor
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204)
Primary endpoint: Group A - Objective Response Rate
A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
Primary endpoint: Best overall response rate (BORR)
Safety and Efficacy Study of Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas
Primary endpoint: Kaplan-Meier Estimate of Overall Survival (OS) at 9 Months
Phase I/II Study of Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
Primary endpoint: Phase I only: Recommended phase II dose (RP2D) of epacadostat with standard of care radiation and chemotherapy in preoperative treatment of locally advanced rectal cancer
A Phase 1b Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies
Primary endpoint: Pharmacodynamic effects as measured by changes in biomarkers in pre- and post-dose tumor and blood specimens
The Trifecta Study: Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
Primary endpoint: Best Overall Response Rate
ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy
Primary endpoint: Objective response rate measured by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer
Primary endpoint: Maximum Tolerated Dose (MTD) of Epacadostat
Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma
Primary endpoint: Number of Patients With Best Objective Response Rate